DOCSLIB.ORG

Playing Hide and Seek with Poorly Tasting Paediatric Medicines: Do Not Forget the Excipients☆

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Playing Hide and Seek with Poorly Tasting Paediatric Medicines: Do Not Forget the Excipients☆ Advanced Drug Delivery Reviews 73 (2014) 14–33 Contents lists available at ScienceDirect Advanced Drug Delivery Reviews journal homepage: www.elsevier.com/locate/addr Playing hide and seek with poorly tasting paediatric medicines: Do not forget the excipients☆ Jennifer Walsh a,⁎,AnneCramb,KatharinaWoertzc, Joerg Breitkreutz c, Gesine Winzenburg d, Roy Turner d, Catherine Tuleu e, On behalf of the European Formulation Initiative (EuPFI) a Jenny Walsh Consulting Ltd, BioCity Nottingham, Pennyfoot Street, Nottingham NG1 1GF, United Kingdom b Drug Product Development, Pfizer Ltd, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom c Institute of Pharmaceutics and Biopharmaceutics, Heinrich-Heine-University Duesseldorf, Building 26.22, Universitaetsstrasse 1,40225 Duesseldorf, Germany d Novartis Pharma AG, Postfach, CH-4002 Basel, Switzerland e Centre for Paediatric Pharmacy Research, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, United Kingdom article info abstract Available online 12 March 2014 The development of paediatric medicines can be challenging since this is a diverse patient population with specific needs. For example, the toxicity of excipients may differ in children compared to adults and children Keywords: have different taste preferences. Acceptable palatability of oral paediatric medicinal products is of great Paediatric importance to facilitate patient adherence. This has been recognised by regulatory authorities and so is becoming Taste masking a key aspect of paediatric pharmaceutical development studies. Many active pharmaceutical ingredients (APIs) Formulation have aversive taste characteristics and so it is necessary to utilise taste masking techniques to improve the Palatability palatability of paediatric oral formulations. The aim of this review is to provide an overview of different Dosage form Excipient approaches to taste masking APIs in paediatric oral dosage forms, with a focus on the tolerability of excipients used. In addition, where possible, the provision of examples of some marketed products is made. © 2014 Elsevier B.V. All rights reserved. Contents 1. Introduction...............................................................15 2. Bitter blockers and taste modifiers.....................................................16 2.1. Bitterreceptorantagonists.....................................................16 2.2. Tastetransductioncascadeblockers.................................................16 2.3. Gapsincurrentknowledgeandtechnologylimitations........................................16 3. Sweeteners and flavouringsystems.....................................................17 3.1. Sweeteners............................................................17 3.2. Flavours..............................................................19 3.3. Safety and toxicity of sweeteners and flavouringagents........................................20 4. ModificationofAPIsolubility.......................................................21 4.1. KeepingtheAPIunionised.....................................................21 4.2. Alternativesolidform.......................................................21 4.3. ChallengestoconsiderformodifyinganAPI.............................................22 5. Create a ‘molecular’ barrieraroundtheAPIbycomplexation.........................................23 5.1. Ion-exchangeresins........................................................23 5.1.1. Safetyandtoxicityofpharmaceuticalgradeionexchangeresins................................23 5.1.2. Formulationssuitableforthepaediatricpopulation......................................24 5.2. Cyclodextrins...........................................................24 5.2.1. Oralsafetyandtoxicityofcyclodextrins...........................................25 5.2.2. Formulationscontainingcyclodextrinsfortastemasking...................................25 ☆ This review is part of the Advanced Drug Delivery Reviews theme issue on "Drug delivery and the paediatric population: where are we at?". ⁎ Corresponding author. Tel.: +44 7757 948052. E-mail addresses: [email protected] (J. Walsh), anne.cram@pfizer.com (A. Cram), [email protected] (J. Breitkreutz), [email protected] (G. Winzenburg), [email protected] (R. Turner), [email protected] (C. Tuleu). http://dx.doi.org/10.1016/j.addr.2014.02.012 0169-409X/© 2014 Elsevier B.V. All rights reserved. J. Walsh et al. / Advanced Drug Delivery Reviews 73 (2014) 14–33 15 6. Apply a physical ‘barrier’ ontheAPIorthedosageform........................................... 26 6.1. Polymer film-coating....................................................... 26 6.1.1. Safetyandtoxicityofcoatingmaterials........................................... 27 6.1.2. Formulationssuitableforthepaediatricpopulation...................................... 28 6.2. Lipidicbarriersystem....................................................... 29 6.2.1. Commonlyusedlipidicexcipientsfortastemasking..................................... 29 6.2.2. Formulationscontaininglipidicexcipientsfortastemasking................................. 29 7. Summaryandconclusions........................................................ 30 References.................................................................. 31 1. Introduction Acceptability is driven by the characteristics of the user (age, ability, disease type and state) and by the characteristics of a medicinal product Acceptable palatability is paramount for paediatric formulations. such as: A survey of over 800 paediatricians showed that unpleasant taste of • palatability medication is a key barrier to compliance for 90.8% of patients with • swallowability (volume/size and shape, integrity of dosage form, acute illness and 83.9% of patients with chronic illness [1].Compliance e.g. functional coating) rates in children have been found to range from 11 to 93%, with major • complexity of manipulation if required factors attributed to formulation and palatability [2].Palatabilityis • the required dose e.g. the dosing volume, number of tablets etc. largely dictated by taste and this is a concern as a significant number • the required dosing frequency and duration treatment of active pharmaceutical ingredients (APIs) on the market and in devel- • the selected administration device opment have aversive taste. This is not considered to be a key issue • the primary and secondary container closure system when developing oral dose forms for adults who can swallow tablets • the actual mode of administration. since such products can be film or sugar-coated, thereby masking the taste of the API. In the paediatric population the issue is accentuated Palatability is one of the main elements of the patient acceptance of a by dysphagia, leading to an increased use of oral dosage forms such as medicinal product. It is defined as the overall appreciation of an (often liquids, (oro-) dispersible and chewable tablets where taste masking oral) medicine by organoleptic properties such as smell, taste, aftertaste becomes a greater challenge. In addition, differences in taste perception, and texture (i.e. mouthfeel), and possibly also vision and sound. It is de- sensitivity and tolerance between adults and children make taste termined by the characteristics of the components (API and excipients) assessment and development of palatable paediatric medications more and the way the API is formulated. Palatability is relevant for other complex. routes of administration e.g. buccal, nasal, inhalation. Thus not only The paediatric population represents a diverse group of patients, should a medicinal product not taste and smell (especially the aroma exhibiting differences in biological and physiological attributes com- on first opening and during consumption) unpleasant, it should have pared to adults. Indeed, children are not merely miniature adults because acceptable mouthfeel (viscosity, grittiness) and appearance (visual as- sensory systems mature postnatally and their responses to certain tastes pect, size and shape, packaging). Thus palatability and indeed accept- differ markedly from adults. Amongst these differences are heightened ability are key considerations when defining the target product profile. preferences for sweet-tasting and greater rejection of bitter-tasting The importance of acceptable palatability has been recognised by foods [3]. In addition, APIs and excipients are metabolized differently regulatory authorities, including the European Medicines Evaluation by children of different ages compared to adults [4]. Therefore the use Agency (EMA) [5]. The French regulatory authorities (Afssaps) launched of certain excipients may not be appropriate or the levels will be restrict- a study designed to determine the acceptability of oral liquid originator ed, which further complicates excipient selection. and generic antibiotics prescribed to ambulatory children [6]. The dis- Indeed, when designing an age-appropriate paediatric medicinal parity in the acceptability of the different antibiotics prescribed, even product, the excipients used should be selected using a benefitriskap- for the same drug has been confirmed by Wollner et al. [7]. proach, encompassing all aspects of the proposed excipients in parallel, Moreover within the requirements of the European Union's Paediat- including: ric Regulation [8], paediatric investigation plan (PIP) guidelines state that the proposed studies of particular relevance to the development • physico-chemical properties (stability, solubility,
Load more

Recommended publications
  • Directory of Companies A
    65 Directory of Companies A An alphabetical list of pharmaceutical companies, as well as manufacturers and suppliers of products and services for Medicinal Chemistry in Europe 3B PHARMACEUTICALS GMBH Magnusstraße 11 12489 BERLIN DE 3M BELGIUM Canadastraat 11, Haven 1005 2070 ZWIJNDRECHT BE 3V-LSI Rubicondreef 18 3561 JC UTRECHT NL of Companies 4SC AG Am Klopferspitz 19a 82152 MARTINSRIED DE A & D INSTRUMENTS LTD Abingdon Science Park OX14 3YX ABINGDON GB ABBVIE DEUTSCHLAND GMBH & CO. KG Knollstrasse 67061 LUDWIGSHAFEN DE Directory ABCR GMBH Im Schlehert 10 76187 Karlsruhe, GERMANY Contact person: Dr. Ute Kiso Tel: +49 721 95061-0 - [email protected] www.abcr.de Gute Chemie. Welcome to abcr. With abcr, you have access to over 260,000 products from the organic, organometallic and inorganic specialty chemicals area. These can be conveniently ordered via our webshop www.abcr.de > Catalogue & Bulk business from grams to tons > Scale up & Commercial manufacturing from our own facility > Sourcing & Logistic management worldwide > Feasibility studies & Synthesis at the laboratory scale > Custom syntheses & Contract Manufacturing ABSORPTION SYSTEMS 440 Creamery Way Suite 300 PA 19341 EXTON US AC IMMUNE SA EPFL Innovation Park Building B 1015 LAUSANNE FR ACCELA CHEMBIO 9823 Pacific Heights Blvd # F 92121 SAN DIEGO US ACRAF S.P.A. Piazzale della Stazione 40 S. PALOMBA - POMEZIA IT ACROS ORGANICS Janssen Pharmaceuticalaan 3a 2440 GEEL BE ACS Journal of Medicinal Chemistry & ACS Medicinal Chemistry Letters Contact person: Janice E. Silverman, Acquisitions Editor Tel: +1 202-577-5975 [email protected] Journal of Medicinal Chemistry – pubs.acs.org/jmc ACS Medicinal Chemistry Letters – pubs.acs.org/acsmedchemlett In 2017 Journal of Medicinal Chemistry is celebrating 60 years of publishing the field’s best peer-reviewed research.
    [Show full text]
  • Contents Page
    Statement of Development Principles: Regeneration Of Boots Campus, Beeston, Nottingham June 2007 STATEMENT OF DEVELOPMENT PRINCIPLES: REGENERATION OF BOOTS CAMPUS, BEESTON, NOTTINGHAM (June 2007) Contents 1. Introduction................................................................................................2 PURPOSE.............................................................................................................................. 2 POLICY CONTEXT................................................................................................................ 3 2. Development Principles ............................................................................4 THE VISION........................................................................................................................... 4 KEY DEVELOPMENT PRINCIPLES ..................................................................................... 4 3. Key Issues ..................................................................................................7 HIGHWAYS AND ACCESS ................................................................................................... 7 BALANCE OF USES ............................................................................................................. 7 LISTED BUILDINGS .............................................................................................................. 9 ENVIRONMENT.....................................................................................................................9
    [Show full text]
  • Acacia Pharma Group
    This document comprises a prospectus (the “Prospectus”) relating to Acacia Pharma Group plc (the “Company” or “Acacia Pharma”) prepared in accordance with the prospectus regulation rules (the “Prospectus Regulation Rules”) of the UK Financial Conduct Authority (the “FCA”) made pursuant to section 73A of the Financial Services and Markets Act 2000, as amended (“FSMA”). This Prospectus has been approved by the FCA as the competent authority under Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and has been filed with and made available to the public in accordance with Rule 3.2 of the Prospectus Regulation Rules. The FCA only approves this Prospectus as meeting the standards of completeness, comprehensibility and consistency imposed by the Prospectus Regulation. Such approval should not be considered as an endorsement of the Company or of the quality of the Ordinary Shares that are the subject of this Prospectus. Investors should make their own assessment as to the suitability of investing in the Ordinary Shares. In addition, this Prospectus has been drawn up as a simplified prospectus in accordance with Article 14 of the Prospectus Regulation. The Belgian Financial Services and Markets Authority (“Belgian FSMA”) was notified of the passporting of this Prospectus in accordance with Article 25 of the Prospectus Regulation. The Company and the Directors, whose names appear on page 39 of this document, accept responsibility for the information contained in this document. To the best of the knowledge of the Company and the Directors, the information contained in this document is in accordance with the facts and this document makes no omission likely to affect its import.
    [Show full text]
  • Chromanone-A Prerogative Therapeutic Scaffold: an Overview
    Arabian Journal for Science and Engineering https://doi.org/10.1007/s13369-021-05858-3 REVIEW-CHEMISTRY Chromanone‑A Prerogative Therapeutic Scafold: An Overview Sonia Kamboj1,2 · Randhir Singh1 Received: 28 September 2020 / Accepted: 9 June 2021 © King Fahd University of Petroleum & Minerals 2021 Abstract Chromanone or Chroman-4-one is the most important and interesting heterobicyclic compound and acts as a building block in medicinal chemistry for isolation, designing and synthesis of novel lead compounds. Structurally, absence of a double bond in chromanone between C-2 and C-3 shows a minor diference from chromone but exhibits signifcant variations in biological activities. In the present review, various studies published on synthesis, pharmacological evaluation on chroman- 4-one analogues are addressed to signify the importance of chromanone as a versatile scafold exhibiting a wide range of pharmacological activities. But, due to poor yield in the case of chemical synthesis and expensive isolation procedure from natural compounds, more studies are required to provide the most efective and cost-efective methods to synthesize novel chromanone analogs to give leads to chemistry community. Considering the versatility of chromanone, this review is designed to impart comprehensive, critical and authoritative information about chromanone template in drug designing and development. Keywords Chroman-4-one · Chromone · Pharmacological activity · Synthesis · Analogues 1 Introduction dihydropyran (ring B) which relates to chromane, chromene, chromone and chromenone, but the absence of C2-C3 dou- Chroman-4-one is one of the most important heterobicyclic ble bond of chroman-4-one skeleton makes a minor difer- moieties existing in natural compounds as polyphenols and ence (Table 1) from chromone and associated with diverse as synthetic compounds like Taxifolin, also known as chro- biological activities [1].
    [Show full text]
  • A Science and Innovation Audit Report for the Midlands Engine
    A Science and Innovation Audit Report for the Midlands Engine, sponsored by the Department for Business, Energy & Industrial Strategy Volume 1: Main Report 01 November 2016 A Science and Innovation Audit Report for the Midlands Engine, sponsored by the Department for Business, Energy & Industrial Strategy Volume 1: Main Report Contents Midlands Engine SIA – the headlines ....................................................................................1 1. Introduction to the Midlands Engine SIA...........................................................................4 2. SIA ‘hypotheses’ and ‘framework’ ...................................................................................10 3. Regional science and innovation assets and excellence..............................................19 4. Innovation strengths and our growth priorities..............................................................30 5. Market and technology drivers of change.......................................................................53 6. Innovation networks and behaviours ..............................................................................59 7. Next Steps – unlocking our productivity potential.........................................................67 A Science and Innovation Audit Report for the Midlands Engine, sponsored by the Department for Business, Energy & Industrial Strategy Volume 1: Main Report Midlands Engine SIA – the headlines 1. In Autumn 2015 the UK Government announced regional Science and Innovation Audits (SIAs) to catalyse
    [Show full text]
  • A Preclinical Evaluation of the Discriminative And
    NP5101_proof ■ 12 June 2013 ■ 1/11 Neuropharmacology xxx (2013) 1e11 Contents lists available at SciVerse ScienceDirect Neuropharmacology journal homepage: www.elsevier.com/locate/neuropharm 1 56 2 A preclinical evaluation of the discriminative and reinforcing 57 3 58 4 properties of lisdexamfetamine in comparison to D-amfetamine, 59 5 fi 60 6 methylphenidate and moda nil 61 7 62 a,* a a a b 8 Q5 David J. Heal , Niki W. Buckley , Jane Gosden , Nigel Slater , Charles P. France , 63 9 David Hackett c 64 10 65 a 11 RenaSci Ltd, BioCity Nottingham, Pennyfoot Street, Nottingham NG1 1GF, UK 66 b University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA 12 c Shire Pharmaceutical Development Ltd, Hampshire International Business Park, Chineham, Basingstoke RG24 8EP, Hampshire, UK 67 13 68 14 69 15 article info abstract 70 16 71 17 Article history: Lisdexamfetamine dimesylate, which consists of L-lysine covalently bound to D-amfetamine, is the first 72 18 Received 12 December 2012 prodrug for treating ADHD. Its metabolic conversion to yield D-amfetamine by rate-limited, enzymatic 73 19 Received in revised form hydrolysis is unusual because it is performed by peptidases associated with red blood cells. Other 74 3 April 2013 20 stimulants shown to be effective in managing ADHD include D-amfetamine, methylphenidate and 75 Accepted 13 May 2013 21 modafinil. All have the potential for misuse or recreational abuse. The discriminative and reinforcing 76 effects of these compounds were determined in rats using a 2-choice, D-amfetamine (0.5 mg/kg, i.p.)- 77 22 Keywords: cued drug-discrimination test, and by substitution for intravenous cocaine in self-administration.
    [Show full text]
  • BIO-SCIENCE FACILITY, LOWER PARLIAMENT STREET, NOTTINGHAM Nottingham City Council Lease the OPPORTUNITY
    Significant Capital Allowance Investment Opportunity BIO-SCIENCE FACILITY, LOWER PARLIAMENT STREET, NOTTINGHAM Nottingham City Council Lease THE OPPORTUNITY Unique opportunity to acquire a new bio-science incubator facility let on a long lease to a major city council with significant capital allowances providing an attractive post tax return. Prominently located at Lower Parliament Street, Nottingham There are estimated £9,750,000 of available capital allowances to a adjacent to the existing Bio-City buildings within Nottingham’s purchaser which at a higher tax rate of 45% are worth £4,387,500 creative quarter. over a 5 year period. 150 years long-leasehold interest at a peppercorn rent from Nottingham City Council is to provide a loan to the purchaser of Nottingham City Council. £11,011,200 for a 5 years period at a fixed interest rate of 4.50% which equates to £495,484 interest per annum. No amortisation required during this period. Construction commenced in August 2015 on the new Biocity Science building over ground and 4 upper floors providing state of the art laboratory and office accommodation and extending to 52,475 sq ft Purchaser equity requirement of £6,748,800 which after interest NIA. Willmott Dixon is the appointed contractor. charges provides a net annual pre tax yield of 3.18%. To be let to Nottingham City Council for 30 years from completion of this transaction on a full repairing and insuring lease at an initial rent of Post tax annual yields are Year 1 - 7.54%, Year 2 - 6.86%, Year 3 - £714,000 per annum equating to £13.61 per sq ft.
    [Show full text]
  • Ep 3138585 A1
    (19) TZZ¥_¥_T (11) EP 3 138 585 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.03.2017 Bulletin 2017/10 A61L 27/20 (2006.01) A61L 27/54 (2006.01) A61L 27/52 (2006.01) (21) Application number: 16191450.2 (22) Date of filing: 13.01.2011 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • Gousse, Cecile GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO 74230 Dingy Saint Clair (FR) PL PT RO RS SE SI SK SM TR • Lebreton, Pierre Designated Extension States: 74000 Annecy (FR) BA ME •Prost,Nicloas 69440 Mornant (FR) (30) Priority: 13.01.2010 US 687048 26.02.2010 US 714377 (74) Representative: Hoffmann Eitle 30.11.2010 US 956542 Patent- und Rechtsanwälte PartmbB Arabellastraße 30 (62) Document number(s) of the earlier application(s) in 81925 München (DE) accordance with Art. 76 EPC: 15178823.9 / 2 959 923 Remarks: 11709184.3 / 2 523 701 This application was filed on 29-09-2016 as a divisional application to the application mentioned (71) Applicant: Allergan Industrie, SAS under INID code 62. 74370 Pringy (FR) (54) STABLE HYDROGEL COMPOSITIONS INCLUDING ADDITIVES (57) The present specification generally relates to hydrogel compositions and methods of treating a soft tissue condition using such hydrogel compositions. EP 3 138 585 A1 Printed by Jouve, 75001 PARIS (FR) EP 3 138 585 A1 Description CROSS REFERENCE 5 [0001] This patent application is a continuation-in-part of U.S.
    [Show full text]
  • Economic Strategy Research Bureau
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Nottingham Trent Institutional Repository (IRep) Biotechnology, life sciences and skills in D2N2: A report for Learn Direct and the D2N2 Local Enterprise Partnership Will Rossiter, David J. Smith, Nikolas Pautz, Daniel McDonald-Junor Economic Strategy Research Bureau Nottingham Business School Nottingham Trent University July 2018 2018 Contents Executive Summary............................................................................................................................ 4 1 Introduction ................................................................................................................................ 6 1.1 Approach ................................................................................................................................. 7 2 What are life sciences and the biotech industry? ....................................................................... 9 2.1 Origins of the Biotechnology industry .................................................................................. 10 2.2 Features of the emerging UK biotechnology industry .......................................................... 13 2.3 The Bioincubator boom of the 2000-2008 ............................................................................ 14 3 Restructuring, Open Innovation and Outsourcing in the Pharmaceutical Industry ................. 17 4 The Decline in Laboratory Technician training ........................................................................
    [Show full text]
  • United States Patent (10 ) Patent No.: US 10,538,797 B2 Thomsen Et Al
    US010538797B2 United States Patent (10 ) Patent No.: US 10,538,797 B2 Thomsen et al. (45 ) Date of Patent : Jan. 21 , 2020 (54 ) METHOD FOR THE BIOTECHNOLOGICAL ( 56 ) References Cited PRODUCTION OF FLAVONE GLYCOSIDE DIHYDROCHALCONES U.S. PATENT DOCUMENTS 9,359,622 B2 * 6/2016 Hilmer C12Y 505/01006 (71 ) Applicant: SYMRISE AG , Holzminden (DE ) 2014/0045233 A1 * 2/2014 Hilmer C12Y 505/01006 435/148 ( 72 ) Inventors : Maren Thomsen , Greifswald (DE ) ; Jakob Ley , Holzminden ( DE ) ; Egon FOREIGN PATENT DOCUMENTS Gross , Holzminden (DE ); Winfried Hinrichs , Greifswald (DE ) ; Uwe EP 2 692 729 A1 2/2014 Bornscheuer, Greifswald (DE ) OTHER PUBLICATIONS ( 73 ) Assignee : SYMRISE AG , Holzminden (DE ) Accession V9P0A9 . Mar. 19 , 2014. Alignment to SEQ ID No. 2 ( Year: 2014 ). * ( * ) Notice : Subject to any disclaimer, the term of this Accession V9P0A9 . Mar. 19 , 2014. Alignment to SEQ ID No. 4 ( Year: 2014 ). * patent is extended or adjusted under 35 Accession KF154734 . Dec. 31, 2013. Alignment to SEQ ID No. 1 . U.S.C. 154 ( b ) by 16 days . ( Year: 2013 ) . * Accession KF154734 . Dec. 31, 2013. Alignment to SEQ ID No. 3 . ( 21 ) Appl. No.: 15 /322,768 ( Year : 2013 ) . * Chica et al. Curr Opin Biotechnol . Aug. 2005; 16 ( 4 ): 378-84 . ( Year : 2005 ) . * ( 22 ) PCT Filed : Jun . 27 , 2015 Singh et al . Curr Protein Pept Sci. 2017 , 18 , 1-11 ( Year: 2017) . * Bornscheuer et al. Curr Protoc Protein Sci. Nov. 2011; Chapter PCT No .: PCT/ EP2015 / 064626 26 :Unit26.7 . ( Year: 2011 ). * ( 86 ) Gall et al, “ Enzymatische Umsetzung von Flavonoiden mit einer $ 371 ( c ) ( 1 ) , backteriellen Chalconisomerase und einer Enoatreduktase ,” Angewandte ( 2 ) Date : Apr.
    [Show full text]
  • Title: the Rise and Rise of Biotech and Life Sciences in Nottingham Will Rossiter, David Smith, & Daniel Mcdonald-Junor
    Title: The rise and rise of biotech and life sciences in Nottingham Will Rossiter, David Smith, & Daniel McDonald-Junor, Nottingham Business School Notable in this years’ Top 200 list are an increasing number of local companies involved in the applications of biotechnology and life sciences – companies like Fresenius Medical , Source Bioscience Limited, and Robinsons Healthcare. Indeed this phenomenon has come to symbolise Nottingham’s reinvention as a post-industrial economy. Recent research at Nottingham Business School has started to explain how it happened. At the start of the millennium, Nottingham looked to be a city facing serious industrial decline. Former mainstays of the local economy like Raleigh, Players, and Royal Ordnance had ceased large scale manufacturing operations in the City and employment in the sector continued to shrink as the balance of the economy shifted towards the service sector. Move forward a decade or two however, and you’ll find a different story. A new development path has been forged through the application of biotechnology and life sciences. That this should have happened in a former manufacturing city in the North Midlands is remarkable. The most obvious symbol of this is BioCity, where more than 75 bioscience-related companies have been established since 2003. Although modest in scale by the standards of bioscience concentrations in London and the South East, the emergence of bioscience in Nottingham is significant. Not least because this momentum has been sustained over a 15-year timeframe and shows no signs of slowing. Indeed BioCity is now the country’s largest life science themed business incubation facility.
    [Show full text]
  • Report Title
    The Midlands Engine Science and Innovation Audit Volume 2: Supporting Annexes 30 September 2016 Science and Innovation Audit Volume 2: Supporting Annexes Contents Annex A: Organisations responding to the e-consultation ................................................. 1 Annex B: Midlands Engine Innovation Group Vision ........................................................... 2 Annex C: Theme-level data ..................................................................................................... 3 Annex D: Thematic workshop notes .................................................................................... 13 Annex E: Further Sci-Val data .............................................................................................. 32 Annex F: Long list of assets ................................................................................................. 46 Annex G: Case examples ...................................................................................................... 68 Annex H: Detailed market priority templates ...................................................................... 78 Annex I: E-consultation responses ...................................................................................... 98 Annex J: Driving competitiveness through our Enabling Competencies ...................... 109 Annex K: Innovation networks and behaviours ............................................................... 112 Science and Innovation Audit Volume 2: Supporting Annexes Annex A: Organisations responding
    [Show full text]